These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32026193)

  • 21. Factors Associated With Prolonged Viral Shedding in Patients With Avian Influenza A(H7N9) Virus Infection.
    Wang Y; Guo Q; Yan Z; Zhou D; Zhang W; Zhou S; Li YP; Yuan J; Uyeki TM; Shen X; Wu W; Zhao H; Wu YF; Shang J; He Z; Yang Y; Zhao H; Hong Y; Zhang Z; Wu M; Wei T; Deng X; Deng Y; Cai LH; Lu W; Shu H; Zhang L; Luo H; Ing Zhou Y; Weng H; Song K; Yao L; Jiang M; Zhao B; Chi R; Guo B; Fu L; Yu L; Min H; Chen P; Chen S; Hong L; Mao W; Huang X; Gu L; Li H; Wang C; Cao B;
    J Infect Dis; 2018 May; 217(11):1708-1717. PubMed ID: 29648602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020.
    Adlhoch C; Delgado-Sanz C; Carnahan A; Larrauri A; Popovici O; Bossuyt N; Thomas I; Kynčl J; Slezak P; Brytting M; Guiomar R; Redlberger-Fritz M; Maistre Melillo J; Melillo T; van Gageldonk-Lafeber AB; Marbus SD; O'Donnell J; Domegan L; Gomes Dias J; Olsen SJ
    Euro Surveill; 2023 Jan; 28(4):. PubMed ID: 36700868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of neuraminidase inhibitors on household transmission in Japanese patients with influenza A and B infection: A prospective, observational study.
    Hirotsu N; Saisho Y; Hasegawa T
    Influenza Other Respir Viruses; 2019 Mar; 13(2):123-132. PubMed ID: 29989680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Comparison of the Efficacy of Baloxavir and Neuraminidase Inhibitors for Patients with Influenza A in Clinical Practice.
    Yoshii N; Tochino Y; Fujioka M; Sakazaki H; Maruyama N; Asai K; Kakeya H; Shintaku H; Kawaguchi T
    Intern Med; 2020; 59(12):1509-1513. PubMed ID: 32536677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of influenza with neuraminidase inhibitors.
    Beard KR; Brendish NJ; Clark TW
    Curr Opin Infect Dis; 2018 Dec; 31(6):514-519. PubMed ID: 30320639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of antiviral treatment in preventing death in severe hospitalised influenza cases over six seasons.
    Domínguez A; Romero-Tamarit A; Soldevila N; Godoy P; Jané M; Martínez A; Torner N; Caylà JA; Rius C;
    Epidemiol Infect; 2018 May; 146(7):799-808. PubMed ID: 29606178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mixed influenza A and B infections complicate the detection of influenza viruses with altered sensitivities to neuraminidase inhibitors.
    Mohr PG; Geyer H; McKimm-Breschkin JL
    Antiviral Res; 2011 Jul; 91(1):20-2. PubMed ID: 21549758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Invasive pulmonary aspergillosis in immunocompetent patients hospitalised with influenza A-related pneumonia: a multicenter retrospective study.
    Chen L; Han X; Li Y; Zhang C; Xing X
    BMC Pulm Med; 2020 Sep; 20(1):239. PubMed ID: 32907585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the Clinical Courses of Patients with Influenza after Neuraminidase Inhibitors Treatment: A Postcard Survey of the 2013-2014 Influenza Season in Osaka.
    Yoshi N; Tocino Y; Fujioka M; Kureya Y; Asai K; Kimura T; Shinataku H; Hirata K
    Osaka City Med J; 2016 Dec; 62(2):29-38. PubMed ID: 30550708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of influenza with neuraminidase inhibitors: virological implications.
    Roberts NA
    Philos Trans R Soc Lond B Biol Sci; 2001 Dec; 356(1416):1895-7. PubMed ID: 11779389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.
    Hayden FG; Osterhaus AD; Treanor JJ; Fleming DM; Aoki FY; Nicholson KG; Bohnen AM; Hirst HM; Keene O; Wightman K
    N Engl J Med; 1997 Sep; 337(13):874-80. PubMed ID: 9302301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors.
    Hatakeyama S; Sugaya N; Ito M; Yamazaki M; Ichikawa M; Kimura K; Kiso M; Shimizu H; Kawakami C; Koike K; Mitamura K; Kawaoka Y
    JAMA; 2007 Apr; 297(13):1435-42. PubMed ID: 17405969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the Clinical Characteristics and Severity of Influenza and Non-influenza Respiratory Virus-Related Pneumonia in China: A Multicenter, Real-World Study.
    Chen L; Han XD; Li YL; Zhang CX; Xing XQ
    Infect Drug Resist; 2020; 13():3513-3523. PubMed ID: 33116670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcomes and Susceptibility to Neuraminidase Inhibitors in Individuals Infected With Different Influenza B Lineages: The Influenza Resistance Information Study.
    van der Vries E; Ip DK; Cowling BJ; Zhang JD; Tong X; Wojtowicz K; Schutten M; Boucher CA
    J Infect Dis; 2016 Jan; 213(2):183-90. PubMed ID: 26160744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuraminidase inhibitors for preventing and treating influenza in children.
    Wang K; Shun-Shin M; Gill P; Perera R; Harnden A
    Cochrane Database Syst Rev; 2012 Jan; 1():CD002744. PubMed ID: 22258949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuraminidase inhibitor susceptibility profile of human influenza viruses during the 2016-2017 influenza season in Mainland China.
    Huang W; Cheng Y; Li X; Tan M; Wei H; Zhao X; Xiao N; Dong J; Wang D
    J Infect Chemother; 2018 Sep; 24(9):729-733. PubMed ID: 29866491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-marketing safety evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir: A drug-use investigation in patients with high risk factors.
    Komeda T; Ishii S; Itoh Y; Sanekata M; Yoshikawa T; Shimada J
    J Infect Chemother; 2016 Oct; 22(10):677-84. PubMed ID: 27497712
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.
    Shobugawa Y; Saito R; Sato I; Kawashima T; Dapat C; Dapat IC; Kondo H; Suzuki Y; Saito K; Suzuki H
    J Infect Chemother; 2012 Dec; 18(6):858-64. PubMed ID: 22644080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuraminidase inhibitor resistance in influenza viruses.
    Reece PA
    J Med Virol; 2007 Oct; 79(10):1577-86. PubMed ID: 17705169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza A (H1N1): retrospective cohort study.
    Hiba V; Chowers M; Levi-Vinograd I; Rubinovitch B; Leibovici L; Paul M
    J Antimicrob Chemother; 2011 May; 66(5):1150-5. PubMed ID: 21393197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.